| Ms Pamela D Donovan, APRN, PMHCNS-BC | |
|
2450 Vinson Hwy Se, Milledgeville, GA 31061-4881 | |
| (478) 445-7904 | |
| Not Available |
| Full Name | Ms Pamela D Donovan |
|---|---|
| Gender | Female |
| Speciality | Clinical Nurse Specialist - Psychiatric/mental Health, Adult |
| Location | 2450 Vinson Hwy Se, Milledgeville, Georgia |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1750600615 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 364SP0809X | Clinical Nurse Specialist - Psychiatric/mental Health, Adult | RN093203 (Georgia) | Primary |
| Entity Name | Department Of Behavioral Health And Developmental Disabilities |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1902030307 PECOS PAC ID: 7416002506 Enrollment ID: O20090825000435 |
News Archive
According to a study presented today at the annual meeting of the Radiological Society of North America (RSNA), the best way to detect cocaine in the body of a human drug courier, known as a mule, is through computed tomography (CT).
The Florida Hospital Association (FHA) and the South Florida Hospital & Healthcare Association (SFHHA) today announce an agreement with the ECRI Institute Patient Safety Organization (PSO) to support the Patient Safety Organization of Florida (PSOFlorida) with patient safety data collection and analysis. PSOFlorida, a component organization of the FHA and the SFHHA, was established to focus on improving the quality of care that hospitals in Florida provide to the state's residents and visitors.
Writing in the Huffington Post's "Impact" blog, Jeremy Kadden, senior legislative manager at InterAction, examines the potential implications of the Obama administration's budget request for U.S. foreign aid.
Watson Pharmaceuticals, Inc. today reported net revenue grew 29 percent for the second quarter ended June 30, 2010 to $875.3 million, compared to $677.8 million in the second quarter 2009. On an adjusted cash basis, net income increased 22 percent to $102.8 million or $0.83 per share, compared to $84.2 million or $0.73 per share in the second quarter 2009. GAAP earnings for the second quarter 2010 were $0.57 per share, compared to $0.46 per share in the prior year period.
Apitope, the European drug discovery and development company focused on treating the underlying cause of autoimmune diseases, today announced completion of recruitment into its second Phase I clinical trial of ATX-MS-1467 in patients with multiple sclerosis (MS).
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Ms Pamela D Donovan, APRN, PMHCNS-BC 2450 Vinson Hwy Se, Milledgeville, GA 31061-4881 Ph: (478) 445-7904 | Ms Pamela D Donovan, APRN, PMHCNS-BC 2450 Vinson Hwy Se, Milledgeville, GA 31061-4881 Ph: (478) 445-7904 |
News Archive
According to a study presented today at the annual meeting of the Radiological Society of North America (RSNA), the best way to detect cocaine in the body of a human drug courier, known as a mule, is through computed tomography (CT).
The Florida Hospital Association (FHA) and the South Florida Hospital & Healthcare Association (SFHHA) today announce an agreement with the ECRI Institute Patient Safety Organization (PSO) to support the Patient Safety Organization of Florida (PSOFlorida) with patient safety data collection and analysis. PSOFlorida, a component organization of the FHA and the SFHHA, was established to focus on improving the quality of care that hospitals in Florida provide to the state's residents and visitors.
Writing in the Huffington Post's "Impact" blog, Jeremy Kadden, senior legislative manager at InterAction, examines the potential implications of the Obama administration's budget request for U.S. foreign aid.
Watson Pharmaceuticals, Inc. today reported net revenue grew 29 percent for the second quarter ended June 30, 2010 to $875.3 million, compared to $677.8 million in the second quarter 2009. On an adjusted cash basis, net income increased 22 percent to $102.8 million or $0.83 per share, compared to $84.2 million or $0.73 per share in the second quarter 2009. GAAP earnings for the second quarter 2010 were $0.57 per share, compared to $0.46 per share in the prior year period.
Apitope, the European drug discovery and development company focused on treating the underlying cause of autoimmune diseases, today announced completion of recruitment into its second Phase I clinical trial of ATX-MS-1467 in patients with multiple sclerosis (MS).
› Verified 4 days ago